Allos Settles Investor Suit Over $686M AMAG Tie-Up
Allos Therapeutics Inc. said Thursday that it had settled a shareholder class action over the company's planned $686 million all-stock merger with AMAG Pharmaceuticals Inc., paving the way for the deal's...To view the full article, register now.
Already a subscriber? Click here to view full article